Is Hikal a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Hikal Ltd is a average quality company .

Is Hikal undervalued or overvalued?

The key valuation ratios of Hikal Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Hikal share price return in the past 10 years?

Hikal Ltd share price has appreciated 14.6% annually (CAGR) over the past ten years.

Is Hikal a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Hikal Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Hikal Ltd - Stock Valuation and Financial Performance

Name: Hikal
Brand: Hikal

BSE: 524735 | NSE: HIKAL | Pharmaceuticals & Drugs | Small Cap

Place order

Hikal Share Price

₹389.25 -2.95 -0.75%
as on 21-Nov'24 16:00

10 Year X-Ray of Hikal:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	12.5%	11.9%	11.9%	12.8%	15.3%	12.4%	16.2%	15.2%	8.5%	7.8%	-
Value Creation Index ⓘ	-0.1	-0.2	-0.2	-0.1	0.1	-0.1	0.2	0.1	-0.4	-0.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	872	926	1,014	1,296	1,590	1,507	1,720	1,943	2,023	1,785	1,806
Sales YoY Gr.	-	6.2%	9.5%	27.8%	22.7%	-5.2%	14.1%	12.9%	4.1%	-11.8%	-
Adj EPS ⓘ	3.4	3.5	5.9	6.5	8.7	7.7	10.7	12.9	6.2	5.6	6
YoY Gr.	-	3.3%	70.3%	9.6%	33.5%	-11.3%	39.8%	20.1%	-51.8%	-9.4%	-
BVPS (₹) ⓘ	34.6	37.2	49.1	54.3	61.3	66.2	75.7	86.6	91.9	96.3	97.6
Adj Net Profit ⓘ	41.5	42.8	72.9	79.8	107	94.5	132	159	76.5	69.3	73
Cash Flow from Ops. ⓘ	102	186	163	139	186	285	229	294	315	187	-
Debt/CF from Ops. ⓘ	5.4	2.7	3.7	4.6	3.6	2.3	2.7	2.3	2.4	4.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	8.3%	2.3%	1.2%	-11.8%
Adj EPS ⓘ	5.9%	-8.3%	-19.4%	-9.4%
BVPSⓘ	12.1%	9.5%	8.4%	4.8%
Share Price	14.6%	29%	-7.7%	44.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	8	7.8	12.5	12.5	15	12	15.1	15.9	7	6	6.2
Op. Profit Mgn % ⓘ	21.1	19.8	19.9	18.9	19.1	18.1	18.8	17.5	12.7	15	16.2
Net Profit Mgn % ⓘ	4.8	4.6	7.2	6.2	6.7	6.3	7.7	8.2	3.8	3.9	4.1
Debt to Equity ⓘ	1.3	1.1	1	1	0.9	0.8	0.7	0.6	0.7	0.7	0.4
Working Cap Days ⓘ	236	229	218	206	203	226	205	198	185	198	89
Cash Conv. Cycle ⓘ	107	102	106	107	105	113	94	90	80	93	21

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.69

Return on Equity has declined versus last 3 years average to 6.10%

Sales growth has been subdued in last 3 years 1.23%

Net Profit has been subdued in last 3 years -19.37%

Sales growth is not so good in last 4 quarters at -3.53%

Latest Financials - Hikal Ltd.

	Standalone	Consolidated
TTM EPS (₹)	6	6
TTM Sales (₹ Cr.)	1,806	1,806
BVPS (₹.) ⓘ	97.6	97.6
Reserves (₹ Cr.) ⓘ	1,179	1,179
P/BV ⓘ	4.02	4.02
PE ⓘ	65.86	65.78

From the Market
52 Week Low / High (₹)	260.65 / 416.15
All Time Low / High (₹)	0.89 / 742.00
Market Cap (₹ Cr.)	4,836
Equity (₹ Cr.)	24.7
Face Value (₹)	2
Industry PE ⓘ	43

Management X-Ray of Hikal:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Hikal

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Hikal

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	872	926	1,014	1,296	1,590	1,507	1,720	1,943	2,023	1,785
Operating Expenses ⓘ	689	745	815	1,054	1,291	1,234	1,398	1,602	1,766	1,518
Manufacturing Costs	121	116	124	159	216	216	233	280	298	304
Material Costs	427	465	509	699	854	776	908	996	1,107	825
Employee Cost	89	108	117	128	136	157	164	203	222	247
Other Costs ⓘ	52	55	66	69	86	85	92	123	138	143
Operating Profit ⓘ	182	181	198	242	298	273	323	341	257	267
Operating Profit Margin (%)	20.9%	19.5%	19.6%	18.7%	18.8%	18.1%	18.8%	17.5%	12.7%	15.0%
Other Income ⓘ	2	2	3	4	2	4	5	5	5	2
Interest ⓘ	60	62	48	49	58	52	36	31	48	56
Depreciation ⓘ	64	67	69	86	93	82	85	96	109	118
Exceptional Items ⓘ	0	0	-4	0	0	-15	0	0	0	0
Profit Before Tax ⓘ	60	53	80	111	149	127	206	219	105	96
Tax ⓘ	19	12	13	34	46	42	73	58	27	26
Profit After Tax	40	41	68	77	103	84	133	160	78	70
PAT Margin (%)	4.6%	4.5%	6.7%	6.0%	6.5%	5.6%	7.7%	8.3%	3.9%	3.9%
Adjusted EPS (₹)	3.3	3.3	5.5	6.3	8.4	6.9	10.8	13.0	6.4	5.6
Dividend Payout Ratio (%)	20%	20%	15%	13%	14%	18%	19%	12%	19%	21%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	532	564	605	669	756	817	933	1,068	1,133	1,188
Share Capital ⓘ	16	16	16	16	25	25	25	25	25	25
Reserves ⓘ	516	547	589	653	732	792	909	1,043	1,109	1,163
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	432	469	550	574	600	561	514	559	663	711
Long Term Debt	201	297	320	297	298	303	263	287	490	423
Short Term Debt	231	172	230	277	302	258	251	273	173	289
Trade Payables	137	128	130	165	160	201	230	249	313	279
Others Liabilities ⓘ	202	138	114	190	259	301	338	452	276	309
Total Liabilities ⓘ	1,304	1,298	1,399	1,597	1,775	1,879	2,016	2,328	2,385	2,487
Fixed Assets
Gross Block	1,096	1,147	737	788	960	1,065	1,127	1,388	1,564	1,802
Accumulated Depreciation	457	524	69	155	247	330	415	508	615	732
Net Fixed Assetsⓘ	639	623	668	634	713	735	713	879	948	1,071
CWIP ⓘ	62	66	63	118	79	161	254	295	412	414
Investmentsⓘ	3	3	4	3	1	1	1	11	5	5
Inventories	314	291	264	303	364	312	267	329	317	304
Trade Receivables	128	112	256	287	350	340	486	438	442	550
Cash Equivalents	14	19	16	27	32	64	37	49	60	21
Others Assetsⓘ	144	183	128	226	236	266	259	327	202	122
Total Assets ⓘ	1,304	1,298	1,399	1,597	1,775	1,879	2,016	2,328	2,385	2,487

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	102	186	163	139	186	285	229	294	315	187
PBT ⓘ	60	53	80	111	149	142	206	219	105	96
Adjustment ⓘ	127	134	127	140	159	136	127	126	163	175
Changes in Working Capital ⓘ	-71	11	-24	-87	-90	46	-58	19	76	-53
Tax Paid ⓘ	-13	-13	-20	-26	-33	-24	-47	-70	-29	-30
Cash Flow From Investing Activity ⓘ	-43	-64	-102	-110	-125	-164	-156	-284	-292	-174
Capex	-49	-59	-105	-106	-128	-158	-158	-273	-302	-204
Net Investments	0	0	0	0	0	0	0	-10	7	0
Others ⓘ	6	-5	3	-4	4	-6	1	-1	3	30
Cash Flow From Financing Activityⓘ	-69	-124	-63	-25	-55	-101	-97	-6	-8	-27
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-18	7	47	-9	-5	20	-27	46	169	-49
Interest Paid ⓘ	-60	-61	-53	-50	-58	-52	-49	-45	-64	-78
Dividend Paid ⓘ	-4	-8	-13	-11	-14	-20	-15	-27	-12	-15
Others ⓘ	13	-61	-44	44	22	-49	-6	20	-100	115
Net Cash Flow ⓘ	-10	-2	-2	4	6	20	-24	4	15	-14

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	9.81	9.32	12.74	12.12	14.46	10.74	15.22	16.04	7.12	6
ROCE (%)	12.5	11.92	11.87	12.81	15.25	12.44	16.15	15.21	8.47	7.82
Asset Turnover Ratio	0.68	0.72	0.77	0.87	0.94	0.82	0.88	0.89	0.86	0.73
PAT to CFO Conversion(x)	2.55	4.54	2.4	1.81	1.81	3.39	1.72	1.84	4.04	2.67
Working Capital Days
Receivable Days	45	47	65	76	73	84	88	87	79	101
Inventory Days	130	118	98	80	77	82	61	56	58	63
Payable Days	115	104	93	77	69	85	87	88	93	131

Hikal Ltd Stock News

Hikal Ltd FAQs

What is the share price of Hikal?

Company share prices are keep on changing according to the market conditions. The closing price of Hikal on 21-Nov-2024 16:00 is ₹389.2.

What is the market cap of Hikal?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:00 the market cap of Hikal stood at ₹4,835.9.

What is the P/E ratio of Hikal?

The latest P/E ratio of Hikal as of 21-Nov-2024 16:00 is 65.86.

What is the P/B ratio of Hikal?

The latest P/B ratio of Hikal as of 21-Nov-2024 16:00 is 4.02.

What is the 52-week high and low of Hikal?

The 52-week high of Hikal is ₹416.1 and the 52-week low is ₹260.6.

What is the TTM revenue of Hikal?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Hikal is ₹1,806 ( Cr.) .

About Hikal Ltd

Established in 1988 Hikal is a reliable partner to companies in the Pharmaceuticals, Biotech, Agrochemicals and Specialty Chemicals industries. They provide world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner. Their advanced infrastructure has been inspected and approved by globally recognized bodies such as the USFDA.

Hikal is a company built on enduring relationships. They are committed to delivering value as a complementary partner. By delivering on this commitment, they have earned the respect and recognition of leading companies from around the world.

Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries. It collaborates with innovator companies and offer solutions in Contract Research, Custom Synthesis and Custom Manufacturing. Its people have extensive expertise in multi-disciplinary project management.

Discovery Research Support It supplies molecules for discovery research on a contract basis. It is the preferred partner of leading multinational companies in different phases of new drug discovery and development. Backed by state-of-the-art instrumentation and an experienced team of scientists, we focus on research on new molecules.
Process Development It has a successful track record in developing non-infringing processes and scaling them up from laboratory to kilo scale to commercial scale production. Its engineering expertise enables it to successfully set up chemical plants, manage and develop a wide range of processes that conform to stringent quality and safety guidelines.
Analytical Method Development It undertakes method validation of new substances. The activities include in-process analysis, identification and quantification of impurities.
Custom Manufacturing It also undertakes custom manufacturing of key intermediates and active substances for pharmaceutical and agrochemical companies worldwide. Its intermediates are being used in new candidate drugs in Phase 1, Phase 2 and Phase 3 stage of clinical trials as well as in commercialized drugs.

Products of the company include:

Pharmaceuticals Products: Gabapentin ,Bupropion Hydrochloride ,Gemfibrozil, Pentoxifylline, Ondansetron Hydrochloride , Ondansetron Base, Triprolidine Hydrochloride ,Acebutolol Hydrochloride, Cinnarizine ,Flunarizine Hydrochloride and Levetiracetam
Agrochemicals Products: Diuron ,Ethion ,Isoproturon ,Metoxuron ,Quinalphos and Thiabendazole

Different divisions of the company are:

Pharmaceuticals Division

Hikal is a partner of choice to the global pharmaceutical industry. They support the pharmaceutical industry from the early lead generation stage till the launch of new chemical entities. Hikal's specialization spans the entire spectrum from conventional synthesis to complex chiral chemistry and is backed by state-of-the-art analytical facilities.

Agrochemicals Division

They are the preferred choice of leading Crop Protection companies in the world. Multinational companies leverage their expertise in developing non-infringing processes for molecules and analytical development.

R&D Division:

R&D is a core competency of Hikal. They assign top most priority to investments in world-class scientists and laboratory instrumentation. Their R&D team is mentored by a Scientific Advisory Board of eminent scientists.

They have an impressive R&D record. Their scientists have published several publications and received patents. They have developed several innovative and cost effective processes for several well known APIs.

Hikal has a global footprint. Its presence in strategic markets enables it to serve the customers better. Hikal has a majority stake in Marsing & Co A/S, a key player in the marketing of Active Pharmaceutical Ingredients (APIs) and raw materials for pharma majors and the chemical industry. Based in Denmark, the company has a distribution network in 100 countries across Europe, Latin America, Africa and the Middle East.

Awards & Achievements:

The companies facilities are ISO 17025, ISO 9000-2000, ISO 14001 and OHSAS 18001 certified.

Recent developments

The domestic credit rating agency, ICRA has assigned LBBB+ to Rs 1,017.4 million and $ 33.1 million long term loans of HIKAL. ICRA has assigned LBBB+ rating outstanding on the Rs. 650 million fund-based bank limits of HIKAL. ICRA also has assigned A2 rating outstanding on the Rs 1,210 million fund based and Rs 480 million non-fund based bank limits.